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ABSTRACT 
Objective: To find out the impact of informal dialogue on the subjects’ willingness to participate in clinical trials. 
Methodology: The awareness, previous participation and willingness to participate in clinical trials were recorded randomly from the patients’ 
relatives who attended Chettinad hospital & Research institute. The participants who responded negatively were selected with their consent and 
given a leaflet containing information about clinical trials. Sufficient time was given for them to read the leaflet and clarify doubts. Their willingness 
to participate in clinical trial was recorded. The subjects who were not willing to participate were individually met and explained about the clinical 
trials outside the official environment. Willingness to participate in clinical trials was recorded again and the difference between before and after 
personal interaction was statistically analyzed. 
Results: 200 subjects (99-males, 101-females) participated in this study. Before informal dialogue, 188 subjects (94%) were unwilling to participate 
and 12 (6%) expressed their willingness. After personal dialogue 137 (68.5%) were ready to participate and 63 (31.5%) were still unwilling to 
participate. The data was analyzed using Fisher’s exact test which showed that informal dialogue significantly improved the willingness to 
participate in clinical trials.  
Conclusion: Informal dialogue outside the formal official environment has positively influenced the decision to take part in clinical trials.  
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INTRODUCTION 
The current challenges for the ethical conduct of clinical trials 
include successful patient recruitment, obtaining informed consent 
from the trial participants, safety of the trial medication and 
adequacy of compensation. Among these, subject recruitment plays a 
key role in clinical trials and providing necessary information to the 
volunteers is vital in subject recruitment. Most of the time, consent is 
taken in an official set up in a CRO or an academic institution which 
can affect the decision making. If consent is taken informally through 
a friendly chat it might influence the decision making. 
Hence the current study is undertaken to find out the role of 
informal dialogue in taking a decision to participate in clinical trial 
by the volunteers.  
Informed consent 
Informed consent is an official acceptance given by the participant to 
take part in clinical trials after fully understanding the details of the 
trial, including the benefits and risks of participation which will be 
explained by the investigator verbally as well as through a written 
document (1). A copy of the consent document is reviewed by the 
IRB before it is presented to the prospective participants. Informed 
consent is an ongoing process that starts before any forms are 
signed and continues through the completion of the study. The 
consent document is only a confirmation of the consent process.  
Patient recruitment in clinical trials is recognized as one of the most 
difficult tasks. (2) Recruitment processes include recruitment in the 
hospital, recruitment through telephonic contact, advertisement like 
flyers and educational program. 
Patients are generally interested in participating in clinical trials but 
due to lack of adequate information about clinical trials, they expect 
their treating physicians to provide detailed information. If patients 
receive such information through their treating physicians, 
enrollment might improve (3).  
 
METHODOLOGY 
The relatives of the patients who attended Chettinad hospital & 
Research institute, Kelambakkam, Chennai were randomly selected.  
The demographic data such as name, age, sex, address, educational 
qualification and income were recorded. Then they were enquired 
about their awareness about clinical trial, previous participation and 
their willingness to participate in clinical trials. The participants who 
responded negatively to all the above three questions were selected 
and asked for their willingness to participate in the present study.  
Those who volunteered to participate in the present study as well as 
who knew the local language were invited to the department of 
pharmacology and given a leaflet containing information about 
clinical trial in the local language. Sufficient time was given for them 
to go through the leaflet and clarify doubts. After that, their 
willingness to participate in clinical trial was recorded. Then they 
were requested to report the next day. Those who were not willing 
were individually met outside the department in the institutional 
visitors’ lounge and informally enquired about their day to day 
activities, the nature of their job, the number of children they have, 
their awareness about clinical trials and then discussed with them 
the benefit, risk, the importance of conducting clinical trials, its 
relevance to human health and how the trial volunteers contribute 
to new drug development which would help the society. Subsequent 
to the discussion, the willingness to participate in clinical trials was 
recorded again from the participants. The difference in the number 
of participants willing to participate in clinical trials before and after 
personal interaction was statistically analyzed. 
RESULTS 
516 subjects were contacted to determine their willingness to 
participate in clinical trial. 
316 subjects rejected participation in the interview. 
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200 showed willingness to participate in the study. 
Among the 200, 99 were males and 101 females. 
The response obtained from the 200 people was classified on the 
basis of age, sex, income, educational qualification and awareness of 
clinical trials. 
 
Fig.1: Willingness between male and female 
Fig.1: Before the explanation was given, 9.09% male offered 
willingness and 90.9% was not willing to take part in trials. Among 
the females, 2.97% offered willingness and 97.02% was not willing 
to participate in the trials. After giving explanation about clinical 
trial process, 70.7% males gave positive reply and 20.2% gave 
negative response to take part in trials, among the females 54.45% 
were willing and 42.57% were not willing to participate in trials. We 
observed that males are willing to participate more than the females. 
Based on the age of the participants they were classified into 5 
groups and the response obtained from each age group was 
segregated. 
 
Fig.2: Willingness among different age groups 
Fig.2: Before explanation, the participants in the age group 25-30 
and 31-35 years expressed willingness to participate in the trial 
while the other age groups expressed unwillingness to participate in 
the study. After personal dialogue 78.43% in 36-40 age group, 
73.17% in 25-30 group, above 50% in the age group 31-35 and 41-
45 and below 50% in group 46-50 were willing to participate in the 
study. It can be inferred that age group 36- 40 (78.43%) showed 
more willingness. 
Based on the educational qualification the participants were divided 
into 6 groups and their responses recorded. 
 
Fig.3: Educational qualification and willingness 
Fig.3: Before explanation, less than 10% of all the categories other 
than those with primary education and 16.66% with primary 
education have given willingness to participate in the trial. After 
explanation, 70% of uneducated people, 69.5% with secondary 
education, 62.5% post graduates, 50% with primary qualification 
and less than 50% of under graduates and professionals have shown 
willingness.  
Based on the income, the participants were divided into 2 groups 
with income above Rs. 10,000 and below Rs. 10,000 and responses 
were recorded. 
 
Fig.4: Willingness among different socio-economic groups 
Fig.4 shows that the subjects earning below Rs. 10,000 per month 
showed more willingness (77.3%) to participate. Participants 
earning above Rs. 10,000 showed less willingness (27.7%). This 
suggests that the socio-economic status of the participant plays an 
important role in their decision to participate. 
 
Fig.5 Willingness to participate before and after explanation 
Fig.5: Overall only 6% of the participants were willing to participate 
in the trial before personal dialogue and after explanation 68.5% 
expressed willingness. More number of males showed willingness 
compared to females. 
The percentage of willing subjects was analysed using Fisher’s extact 
test and the P value was < 0.01 indicating statistically significant 
difefrence in the results between before explanation and after 
explanation. 
DISCUSSION 
Among the causes for delay in completion of clinical trial, more than 
25% delay is due to failure of subject recruitment (4). “In the UK, 
only 31% of CTs sponsored by the Medical Research Council and the 
Health Technology Assessment Programme achieved their original 
recruitment target; furthermore, 55% did not reach the revised 
target (5). In 333 concluded UK public and charity sponsored cancer 
trials that were started between 1971 and 2000, only 48% reached 
the planned sample size, whereas 20% of the CTs recruited less than 
25% of the planned sample size” (6).  
“Recent US data showed that among 180 National Cancer Institute 
(NCI) Cancer Evaluation Program-sponsored CTs, activated between 
2000 to 2004 and closed to accrual, 36% and 62% of phase 2 and 3 
trials, respectively, did not attain their recruitment goals” (7). 
Similar data are not found regarding clinical trials conducted in 
India.  
Poor recruitment will result in failure to conduct clinical trials and it 
may lead to delay in introducing new drugs in to the market which in 
turn may have an impact on patient’s treatment and health. 
Participating in clinical trials may provide timely intervention by the 
administration of the prospective new drug to potential study 
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subjects and result in therapeutic benefit and the delay may deprive 
this benefit to the patients of especially incurable diseases.  
Hence successful recruitment of the target number of participants 
within the stipulated time period is one of the key factors for the 
completion of clinical trials. The reasons for incomplete recruitment 
include subjects’ unawareness about clinical trials, failure to get 
informed consent, stringent inclusion criteria, the time subjects have 
to spend in CRO, the frequency of visits, the distance to CRO and the 
adverse effects of drugs. These causes have to be handled 
individually and strategies have to be evolved to overcome these 
barriers. 
Taking informed consent is a difficult task at times for the 
investigator. Informed consent is a two edged weapon which may 
facilitate or prevent the subjects’ participation. Detailed description 
of the entire process of clinical trial including the probable adverse 
effects is both an ethical and regulatory requirement. Detailed 
information about the clinical trials may adversely affect subjects’ 
decision to participate. Adams et al have reported from a two-year 
study conducted in Tibet that the presentation of informed consent 
protocols will be more effective if it is more flexible and focuses on 
the intent rather than the specific information of the informed 
consent process(8). Innovation in informed consent taking is 
essential to improve subject recruitment. 
Usually the volunteers are interviewed in a CRO, an official 
organization with specific rules and regulations like specific entry, 
exit points and other restrictions. In this official setup even if the 
investigators explain without any bias all the details of clinical trials, 
it may not be possible for the subjects to freely ask questions and 
clarify doubts. Most of these subjects are uneducated and naïve. The 
cultural barriers may also prevent them from freely conversing with 
the new person in an unfamiliar setting. A friendly chat in an 
informal setting may help the subjects to talk freely and take the 
right decision. 
Hence this study was undertaken and the subjects who took part in 
this survey belong to different socio economic and educational 
status. Men predominantly participated in this study. We have 
observed that before personal dialogue the percentage of subjects 
willing to participate in clinical trial was only 6 %( 12 among the 
200 subjects). 
After personal interaction clearly explaining the benefits and the 
risks and how they would be taken care of if any adverse event 
occurs and how they could contribute to the health of the society by 
taking part in clinical trials, the number of subjects who were willing 
improved significantly (137 out of 200 subjects). 
The present study has shown that mostly males and subjects in the 
age group of 36 – 40 yrs, uneducated and who belong to lower 
income group(below Rs 10000 per month) were ready to participate 
in clinical trials. This observation is in line with earlier views 
regarding subject’s enrollments in clinical trials.  
The probable reasons could be the patriarchal society to which they 
belong, the faith they have in the medical personnel and the social 
responsibility they have as a citizen to contribute to the health of the 
society. 
The percentage of subjects who offered willingness after detailed 
informal chat improved from 6% to 68.5%. (P value < 0.01) Such a 
marked increase in the percentage of willing subjects could be due to 
the environment they had to intervene, ask questions and clarify. 
Though they might have the same opportunity in an official 
environment, the confidence and the closeness created by the 
informal setting, the lack of hierarchy and the concern and interest 
shown by the investigator in their personal life could have 
contributed to the change in the decision making.  
CONCLUSION 
The results of the present study thus have shown that informal chat 
with the subject outside the official setting has significantly 
improved the decision making to participate in clinical trials. 
Such an informal dialogue can be used as tool to improve informed 
consent without compromising the ethical principles of 
voluntariness, information and comprehension.  
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